/Investor DB

Claris Ventures — 2025 Investments

3 investments dated 2025 · listed companies and verified rows first · show all

Lever Bioleverbio.cominMay 2025✓ verified

Lever Bio develops immunotherapy drug candidates in immuno-oncology, partnering with top researchers and academic institutions to translate discoveries into cancer immunotherapies.

BiotechDeep TechHealthtechMedical Devices

Pietro Puglisi(Chief Executive Officer)in

Co-investorsExor VenturesItalian Angels for GrowthClub degli InvestitoriOra Global

Haptena Therapeuticshaptena.cominDec 2025

Haptena Therapeutics is a biotech company developing next-generation immunotherapies for oncogene-driven, genetically defined cancers, starting with KRAS-driven tumors.

BiotechHealthtech

Chiara Ambrogio(Co-founder)Roberto Chiarle(Co-founder)

IAMA Therapeuticsiamatherapeutics.comApr 2025 · $17M

IAMA Therapeutics develops small-molecule drugs for autism, epilepsies, and other central nervous system disorders, focusing on inhibiting cation-chloride cotransporters to correct atypical brain activity.

BiotechDeep Tech

Co-investorsCDP Venture CapitalIndaco Venture Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.